



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**

**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS SCIENTIST DELIVERS PRESENTATION  
TO DETECTIVES AT NEW SCOTLAND YARD**

**SARASOTA, Fla., June 26, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that Matthew Thomas, Ph.D., the Company's Senior Scientist, delivered a lecture on forensics technology for law enforcement to detectives at the New Scotland Yard in London.

"We are certainly pleased that Dr. Thomas was invited to present an in-depth overview of our DNAWitness™ technology for law enforcement to New Scotland Yard," said DNAPrint President and Chief Executive Officer Richard Gabriel. "We enjoy an excellent working relationship with this legendary law enforcement agency and welcomed the opportunity to share the Company's expertise with its senior detectives."

DNAPrint Genomics has been working with New Scotland Yard since March of 2004, utilizing DNAWitness as part of an effort to capture the so-called Minstead Rapist, an elusive serial sex offender who is suspected of breaking into the homes of more than 90 women, sexually assaulting many of his victims, in an area south of London since 1992. The investigation led to the establishment of "Operation Minstead," the largest investigation of its kind ever mounted by the Metropolitan Police.

"The investigation has drawn heavily upon forensic resources for psychological and geographic crime profiles," Dr. Thomas stated on his return from London. "Investigators are utilizing our DNAWitness technology to analyze samples left at the crime scene to better understand possible populations and personal characteristics that would be relevant to the case."

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWitness (TM), RETINOME(TM), AncestrybyDNA(TM) and EuroDNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests

(MORE)

offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###